AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$EVH

Evolent Health, Inc. Q3 2026 Earnings Call Summary

Evolent Health reported 11% sequential revenue growth driven by Highmark Performance Suite and contractual adjustments. MER improved to 93%. Management prioritizes margin expansion and cash generation, with oncology expected to represent over 70% of revenue by 2027. AI platform scales, processing 1M cases annually. Management reiterated 2027 Adjusted EBITDA confidence of $150M+ and plans $50M debt reduction by 2026 year-end.

Original reporting
finance.yahoo.com
Published Nov 5, 2026, 11:49 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 6, 2026, 12:08 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Evolent Health, Inc. Q3 2026 Earnings Call Summary — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$EVHBullishMed
01

Why it matters

The new guidance and capital‑allocation plan are likely to be priced into the stock, offering a medium‑term trade idea.

02

Market read

Fresh EBITDA guidance and debt‑paydown plan create a catalyst for EVH, with potential upside for investors focused on healthcare tech.

03

What to watch

Potential Medicaid policy changes could materially affect revenue; regulatory risk remains.

Relevance 7/10Novelty 7/10Timing: post‑earnings call

Background

Evolent Health (EVH) provided an earnings‑call summary highlighting Q3 performance, strategic focus on margin, AI initiatives, and 2027 outlook.

Company-level read

Ticker impact

$EVHBullishHigh confidence
Context

Evolent Health disclosed 2027 Adjusted EBITDA guidance of $150M+ and a $50M debt reduction plan during its Q3 2026 earnings call.

Expected impact

likely upward pressure as investors price in higher EBITDA outlook and improved balance sheet.

Evidence & confidence

Guidance and debt‑paydown are fresh, material disclosures that can shift valuation expectations.

Market effects

Sector

Higher EBITDA guidance may lift sentiment for the broader health‑tech and managed‑care services sector.

Regional

U.S. healthcare services investors could see modest inflows.

Global

Limited to U.S. market; no direct global macro effect.

Counterpoint

What could challenge this read

If AI cost‑savings and debt reduction lag, guidance may be overly optimistic, risking downside.

Key entities

  • company
    Evolent Health, Inc.

    U.S. listed health‑technology firm providing managed‑care solutions.

Read at source← All news

StoryEvolent Health posts Q3 2026 loss, lifts full‑year Adjusted EBITDA guidance

Also covered by

5 outlets

Related articles

$EVHMedAI 8/10

EVH Q3 2026 deep dive: ongoing AI investment and customer expansion shape outlook

EVH reported Q3 2026 revenue of $725.4M (51.3% YoY growth, in line with estimates) and adjusted EPS of $0.06 (in line). Adjusted EBITDA was $34.26M, beating estimates by 3.1%. The company reconfirmed full-year revenue guidance of $2.65B and raised EBITDA guidance to $132.5M. Sales volumes fell 4.2% YoY, while operating margin declined to -0.9%. EVH expanded its AI platform, Oncology care, and National payer scale, citing cost savings and margin expansion potential.

finance.yahoo.com
$EVHMedAI 8/10

Evolent Health (EVH) Q3 2026 Earnings Call Transcript

Evolent Health (EVH) reiterated its full-year revenue guidance of $2.6B-$2.7B and raised Adjusted EBITDA guidance to $130M-$135M. The company reported customer contract renewals and expansions, including a 4-year renewal with its largest Surgical Management customer and expansions in oncology and specialty services.

finance.yahoo.com
$EVHMed

Evolent Health: Q3 Earnings Snapshot

Evolent Health (EVH) reported a Q3 loss of $23.6M, or 21 cents per share, with adjusted earnings of 6 cents per share, meeting expectations. Revenue was $725.4M, below the $734.3M forecast. The company expects full-year revenue between $2.6B and $2.7B.

finance.yahoo.com
$EVHMed

Evolent Announces Third Quarter 2026 Results

Evolent Health, Inc. (EVH) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Evolent Announces Third Quarter 2026 Results WASHINGTON (November 5, 2026) – Evolent Health, Inc. (NYSE: EVH) (“Evolent” or the “Company”), a company that specializes in better health outcomes for people with complex conditions through proven solutions that make heal

SEC EDGAR 8-K